<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en" article-type="rapid-communication" dtd-version="2.3">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">molbank</journal-id>
      <journal-title>Molbank</journal-title>
      <abbrev-journal-title abbrev-type="publisher">Molbank</abbrev-journal-title>
      <abbrev-journal-title abbrev-type="pubmed">Molbank</abbrev-journal-title>
      <issn pub-type="epub">1422-8599</issn>
      <publisher>
        <publisher-name>MDPI</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.3390/M513</article-id>
      <article-id pub-id-type="publisher-id">molbank-2006-M513</article-id>
      <article-categories>
        <subj-group>
          <subject>Short Note</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Synthesis of 1-benzyl-3-chloro-4-(3,4,5-trimethoxyphenyl)azetidin-2-one</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Yang</surname>
            <given-names>Zhaoqi</given-names>
          </name>
          <xref rid="c1-molbank-2006-M513" ref-type="corresp">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sun</surname>
            <given-names>Pinhua</given-names>
          </name>
        </contrib>
      </contrib-group>
      <aff id="af1-molbank-2006-M513">Institute of New Drug Research, Jinan University College of Pharmacy, Guangzhou 516032, China</aff>
	  <author-notes>
        <corresp id="c1-molbank-2006-M513"><label>*</label> Author to whom correspondence should be addressed; e-mail: <underline><email>pharmacydoctor@163.com</email></underline></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>01</day>
        <month>12</month>
        <year>2006</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>12</month>
        <year>2006</year>
      </pub-date>
      <volume>2006</volume>
      <issue>6</issue>
      <elocation-id>M513</elocation-id>
      <history>
        <date date-type="received">
          <day>06</day>
          <month>07</month>
          <year>2006</year>
        </date>
        <date date-type="accepted">
          <day>03</day>
          <month>08</month>
          <year>2006</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2006 MDPI.</copyright-statement>
        <copyright-year>2006</copyright-year>
        <license>
          <p>All rights reserved.</p>
        </license>
      </permissions>
      <abstract>
        <p>Combretastatin A-4, isolated from a South African tree Combretum caffrum, is one of the most potent anti-tomour agents. In this paper, an analogue of Combretastatin A-4 was synthesized in order to improve the anti-tumour activity. Compound was characterized by IR and <sup>1</sup>HNMR.</p>
      </abstract>
      <kwd-group>
        <kwd>Combretastatin A-4</kwd>
		<kwd>Synthesis</kwd>
		<kwd>analogue</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introduction</title>
      <p>Cancer is the second major cause of death in the world. Although many researches about cancer all around the world, researchers still have no way to cure for most forms of human cancer. One common characteristic for all types of cancer is the requirement of a suitable blood supply. Tumor vasculature is an important and rapidly emerging target for anticancer therapy. Therefore, vasculature of tumor is nowadays intensively preclinically and clinically investigated as a new potential target for anti-tumor therapeutic strategy. [<xref ref-type="bibr" rid="B1-molbank-2006-M513">1</xref>,<xref ref-type="bibr" rid="B2-molbank-2006-M513">2</xref>,<xref ref-type="bibr" rid="B3-molbank-2006-M513">3</xref>,<xref ref-type="bibr" rid="B4-molbank-2006-M513">4</xref>]</p>
      <p>Combretastatin A-4 (CA-4), a natural compound isolated from the bark of the South African bush willow tree <italic>Combretum caffrum</italic> (Combretaceae), is one of the most potent anti-vascular agents. [<xref ref-type="bibr" rid="B5-molbank-2006-M513">5</xref>] It has also been demonstrated to shut down tumor vasculature rapidly, whereas the blood flow to normal tissues was much less affected. [<xref ref-type="bibr" rid="B6-molbank-2006-M513">6</xref>,<xref ref-type="bibr" rid="B7-molbank-2006-M513">7</xref>] CA-4 has received a great deal of attention due to its relatively simple structure, high potency as cytotoxic agents and antivascular activity. A number of CA-4 analogues has been synthesized and evaluated. [<xref ref-type="bibr" rid="B6-molbank-2006-M513">6</xref>] <italic>&#x3B2;</italic>-lactam is a very useful pharmacophore existed in a lot of drugs and Banik et al. [<xref ref-type="bibr" rid="B8-molbank-2006-M513">8</xref>] reported synthesis of <italic>&#x3B2;</italic>-lactam analogues entry to novel anticancer agents. In view of these facts, a new analogue of CA-4 is synthesized in this paper. The biological evaluation of the compound would be done quickly.</p>
	  <p><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2006-M513-i001.tif"/></p>
    </sec>
    <sec sec-type="methods">
      <title>Experimental</title>
      <p>Melting points were uncorrected and were measured with micro-melting point apparatus XT-4. IR spectra (KBr) were obtained on a Thermo Nicolet Nexus 470 FT-IR spectrometer. <sup>1</sup>H NMR spectra were determined on a Varian Mecurry 300 spectrometer using CDCl<sub>3</sub> as solvent and tetramethylsilane (TMS) as internal reference. Preparative separations were performed by flash chromatography on silica gel (Qingdao, 200~300mesh).</p>
      <p>Phenyl-N-(3,4,5-trimethoxybenzylidene) methanamine (2 g, 7mmol) and triethylamine (3.9ml, 28mmol) dissolved in 50ml anhydrous DCM, and the solution was stirred in an ice-salt bath under argon atmosphere. The mixture was stirred for a few minutes, and then a solution of 2-chloroacetyl chloride (1.7ml, 21mmol) in 20ml DCM was added dropwise, and the reaction mixture was kept in ice-salt bath stirred 24 hours. Diluted hydrochloric acid was added and stirred 5 minutes, and then washed with 3&#xD7;30ml saturated NaHCO<sub>3</sub>, 3&#xD7;30ml saturated brine, 40&#xD7;2ml water. The organic layer was dried with anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The residual was purified by silicon-gel chromatography (25% EtOAC/petroleum ether) to afford the target compound (0.38g, 15&#xFF05;) as a white solid.</p>
      <p>Melting Point: 78&#x2103;&#xFF5E;80&#x2103;.</p>
      <p>TLC: R<sub>f</sub> (silica; ethyl acetate: petroleum ether, 1:2) 0.55.</p>
      <p>IR&#xFF08;KBr cm<sup>-1</sup>): 2996, 2944, 2841, 1694, 1637, 1580, 1462, 1417, 1230, 1020, 764.</p>
      <p><sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): &#x3B4;= 3.83 (s, 6H, (OCH<sub>3</sub>)<sub>2</sub>). 3.87 (s, 3H, OCH<sub>3</sub>). 4.00 (d, H,-CHCl-). 4.33 (s, H,-CH-). 4.55 (s, H,-CH-). 4.76 (d, H,-CH-). 6.38 (s,2H, PhH). 7.15~7.35 (m,5H,PhH).</p>
    </sec>
  </body>
  <back>
    <app-group>
      <app id="app1-molbank-2006-M513">
        <title>Supplementary materials</title>
        <supplementary-material id="molbank-2006-M513-s001" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2006-M513-s001-mod.mol">
        <label>Supplementary File 1</label>
        </supplementary-material>
		<supplementary-material id="molbank-2006-M513-s002" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2006-M513-s001.mol">
        <label>Supplementary File 2</label>
        </supplementary-material>
	  </app>
    </app-group>
    <ack>
      <title>Acknowledgment</title>
      <p>The author is grateful to Professor Xianming Hu of the State Key Laboratory of Virology, College of Pharmacy, Wuhan University for experimental advice.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="B1-molbank-2006-M513">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hori</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Saito</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Kubota</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <source>B. J. Cancer</source>
          <year>2002</year>
		  <volume>86</volume>
          <issue>10</issue>
		  <fpage>1604</fpage>
		  <lpage>1614</lpage>
        </citation>
      </ref>
      <ref id="B2-molbank-2006-M513">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Monk</surname>
              <given-names>K. A.</given-names>
            </name>
            <name>
              <surname>Siles</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Hadimani</surname>
              <given-names>M. B.</given-names>
            </name>
          </person-group>
          <source>Bioorg. Med. Chem.</source>
          <year>2006</year>
          <volume>14</volume>
          <issue>9</issue>
          <fpage>3231</fpage>
          <pub-id pub-id-type="doi">10.1016/j.bmc.2005.12.033</pub-id>
          <pub-id pub-id-type="pmid">16442292</pub-id>
        </citation>
      </ref>
      <ref id="B3-molbank-2006-M513">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Neri</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Bicknell</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <source>Nat. Rev. Cancer</source>
          <year>2005</year>
          <volume>5</volume>
          <issue>6</issue>
          <fpage>436</fpage>
          <pub-id pub-id-type="doi">10.1038/nrc1627</pub-id>
          <pub-id pub-id-type="pmid">15928674</pub-id>
        </citation>
      </ref>
      <ref id="B4-molbank-2006-M513">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gaya</surname>
              <given-names>A. M.</given-names>
            </name>
            <name>
              <surname>Rustin</surname>
              <given-names>G.J. S.</given-names>
            </name>
          </person-group>
          <source>Clin. Oncol.</source>
          <year>2005</year>
          <volume>17</volume>
          <issue>4</issue>
          <fpage>227</fpage>
        </citation>
      </ref>
      <ref id="B5-molbank-2006-M513">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hsieh</surname>
              <given-names>H. P.</given-names>
            </name>
            <name>
              <surname>Liou</surname>
              <given-names>J. P.</given-names>
            </name>
            <name>
              <surname>Mahindroo</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <source>Curr. Pharm. Des.</source>
          <year>2005</year>
          <volume>11</volume>
          <issue>13</issue>
          <fpage>1655</fpage>
        </citation>
      </ref>
      <ref id="B6-molbank-2006-M513">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nam</surname>
              <given-names>N. H.</given-names>
            </name>
          </person-group>
          <source>Curr. Med. Chem.</source>
          <year>2003</year>
          <volume>10</volume>
          <issue>17</issue>
          <fpage>1679</fpage>
          <lpage>1722</lpage>
        </citation>
      </ref>
      <ref id="B7-molbank-2006-M513">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tozer</surname>
              <given-names>G. M.</given-names>
            </name>
            <name>
              <surname>Prise</surname>
              <given-names>V.E.</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <source>Cancer Res.</source>
          <year>2001</year>
		  <volume>61</volume>
          <issue>17</issue>
          <fpage>6413</fpage>
        </citation>
      </ref>
      <ref id="B8-molbank-2006-M513">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Banik</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Becker</surname>
              <given-names>F. F.</given-names>
            </name>
            <name>
              <surname>Banik</surname>
              <given-names>B. K.</given-names>
            </name>
          </person-group>
          <source>J. Med. Chem.</source>
          <year>2003</year>
          <volume>46</volume>
          <issue>1</issue>
          <fpage>12</fpage>
        </citation>
      </ref>
    </ref-list>
  </back>
</article>